Shapiro Roger L, Smeaton Laura, Lockman Shahin, Thior Ibou, Rossenkhan Raabya, Wester Carolyn, Stevens Lisa, Moffat Claire, Arimi Peter, Ndase Patrick, Asmelash Aida, Leidner Jean, Novitsky Vladimir, Makhema Joseph, Essex Max
Beth Israel Deaconess Medical Center, Division of Infectious Diseases, Boston, Massachusetts 02215, USA.
J Infect Dis. 2009 Feb 1;199(3):414-8. doi: 10.1086/596034.
Risk factors for mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) via breast-feeding were evaluated in a randomized trial. HIV-infected women and their infants received zidovudine as well as single-dose nevirapine or placebo. Infants were randomized to formula-feed (FF) or breast-feed (BF) in combination with zidovudine prophylaxis. Of 1116 at-risk infants, 6 (1.1%) in the FF group and 7 (1.3%) in the BF group were infected between birth and 1 month (P=.99). Maternal receipt of nevirapine did not predict early MTCT in the BF group (P=.45). Of 547 infants in the BF group at risk for late MTCT, 24 (4.4%) were infected. Maternal HIV-1 RNA levels in plasma (P<.001) and breast milk (P<.001) predicted late MTCT. These findings support the safety of 1 month of breast-feeding in combination with maternal and infant antiretroviral prophylaxis. Trial registration. ClinicalTrials.gov identifiers: NCT00197691 and NCT00197652.
在一项随机试验中评估了人类免疫缺陷病毒(HIV)通过母乳喂养发生母婴传播(MTCT)的风险因素。HIV感染的妇女及其婴儿接受了齐多夫定以及单剂量奈韦拉平或安慰剂。婴儿被随机分为配方奶喂养(FF)或母乳喂养(BF)并联合齐多夫定预防用药。在1116名有风险的婴儿中,FF组有6名(1.1%)、BF组有7名(1.3%)在出生至1个月期间被感染(P = 0.99)。BF组中母亲接受奈韦拉平并不能预测早期MTCT(P = 0.45)。在BF组有晚期MTCT风险的547名婴儿中,24名(4.4%)被感染。母亲血浆中的HIV-1 RNA水平(P<0.001)和母乳中的HIV-1 RNA水平(P<0.001)可预测晚期MTCT。这些发现支持了母乳喂养1个月联合母婴抗逆转录病毒预防用药的安全性。试验注册。ClinicalTrials.gov标识符:NCT00197691和NCT00197652。